Abstract
Until the publication of two pivotal trials, there were no treatment options available that did prolong the overall survival in men with hormone refractory prostate cancer (HRPC). Currently, docetaxel-based cytotoxic treatment is considered as a standard of care in all the patients with progressive metastatic HRPC. The use of this treatment regimen renders an equal survival benefit in all the subgroups of patients; however, there is a substantial difference in the overall survival between the subgroups. This review addresses the optimal timing of the cytotoxic treatment in asymptomatic patients with HRPC. (C) 2008 Elsevier Ltd. All rights reserved.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 1193-1197 |
| Number of pages | 5 |
| Journal | European Journal of Cancer |
| Volume | 44 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research programs
- EMC MM-03-49-01
- EMC MM-03-86-08
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver